3-iodobenzylguanidine has been researched along with fenretinide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ames, MM; Buhrow, SA; Cohn, SL; Jackson, H; Kitchen, BJ; London, WB; McGovern, RM; McGrady, P; Naranjo, A; Parisi, MT; Reid, JM; Reynolds, CP; Shulkin, B; Sondel, PM; Stranzinger, E; Villablanca, JG; Yanik, GA | 1 |
1 trial(s) available for 3-iodobenzylguanidine and fenretinide
| Article | Year |
|---|---|
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
Topics: 3-Iodobenzylguanidine; Administration, Oral; Adolescent; Antineoplastic Agents; Capsules; Child; Child, Preschool; Disease-Free Survival; Female; Fenretinide; Humans; Infant; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neuroblastoma; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed; Young Adult | 2011 |